Key Highlights
- Fresh post hoc analyses on Wegovy (semaglutide) were unveiled at the ADA 2026 Scientific Sessions, examining sleep apnea, asthma, hypertension, and hepatic function.
- Amycretin phase 2 trial results demonstrated weight reduction up to 14.6% and A1C decline of 1.71 percentage points across 36 weeks.
- As a unified dual GLP-1 and amylin receptor agonist, amycretin is advancing toward phase 3 development.
- Novo Nordisk shares have plummeted approximately 68% during the last two years amid intensifying competition and research disappointments.
- The oral formulation of Wegovy is drawing new users, while experimental therapies like UBT251 expand options beyond semaglutide-based treatments.
Shares of Novo Nordisk have plunged nearly 68% across the last 24 months. For a pharmaceutical giant that once dominated the obesity medication landscape, this represents a dramatic reversal. Yet beneath the surface, several noteworthy developments are unfolding.
During the American Diabetes Association’s 2026 Scientific Sessions, the Danish drugmaker unveiled multiple post hoc assessments derived from its SELECT, STEP, ESSENCE, and OASIS study programs. These analyses examined semaglutide’s impact — the compound powering both Wegovy and Ozempic — on health conditions extending well beyond weight management.
One particular evaluation revealed that semaglutide injection at 2.4 mg dosing correlated with a 52% reduction in obstructive sleep apnea incidence versus placebo, registering a hazard ratio of 0.48. Among trial participants free from OSA initially, only 30 developed the condition in the semaglutide arm compared to 65 receiving placebo.
A separate examination targeted asthma outcomes. Individuals with confirmed cardiovascular disease, asthma, and obesity receiving semaglutide experienced fewer asthma-related complications — 27 events versus 46 in the control arm, yielding a hazard ratio of 0.58. Additionally, high-sensitivity C-reactive protein declined by 38.9%, signaling reduced systemic inflammation.
Regarding hypertension management, combined STEP trial datasets indicated semaglutide lowered systolic blood pressure by approximately 5.48 mmHg beyond placebo effects in subjects with uncontrolled hypertension. Diastolic readings decreased by 2.73 mmHg.
Hepatic health findings from the ESSENCE program demonstrated sustained enhancement in cardiometabolic biomarkers and liver function parameters through week 72, independent of initial glycemic status.
Amycretin Phase 2 Results Generate Momentum
Perhaps more significant is the amycretin development. Novo Nordisk published phase 2 findings indicating this compound — engineered as a dual-acting GLP-1 and amylin receptor agonist within a single molecular structure — achieved weight reduction reaching 14.6% alongside A1C reduction of 1.71 percentage points from a 7.8% starting point during the 36-week observation period. Placebo participants experienced merely 2.1% weight decrease.
Importantly, higher dosages showed no evidence of weight loss plateau formation. This dose-responsive pattern represents precisely what analysts and clinical researchers anticipate before advancing to phase 3 investigations.
Contrasting with CagriSema, which merges two distinct molecular entities, amycretin operates as a singular molecule. This architectural difference potentially translates to enhanced effectiveness and streamlined production processes. The company intends to pursue both subcutaneous and oral delivery systems.
Factors Behind Recent Stock Weakness
The preceding two-year period has proven challenging. Eli Lilly’s Zepbound demonstrated superior weight reduction outcomes in comparative studies, while CagriSema underperformed against management’s 25% average weight loss projection. It subsequently failed in direct comparison trials versus Zepbound.
Financial performance has suffered correspondingly. Novo Nordisk lowered its financial outlook repeatedly throughout 2025 and presently anticipates revenue contraction for fiscal 2026.
The oral Wegovy tablet has provided encouraging results, attracting patients previously hesitant about injectable therapies. Developmental candidate UBT251, functioning as a triple gut hormone agonist, has produced favorable phase 2 outcomes in Chinese markets.
Coming catalysts include amycretin phase 3 protocol specifications and potential comparative effectiveness data against rival GLP-1 therapeutics.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
